Talaris Slashes Workforce, Shifts Focus in Restructuring

Talaris Therapeutics is shifting its focus and its pipeline in a restructuring initiative that includes cutting its workforce by one-third.

In the Thursday morning announcement, the biotech stated it will also drop two trials studying its lead candidate, FCR001, in kidney transplant recipients. Talaris cited the pace of enrollment and the associated timeline to critical milestones as the motivation behind its decision.